期刊文献+

硫酸氢氯吡格雷的手性及多晶型结构剖析 被引量:1

Analysis of polymorphs and chiral structure of Clopidogrel hydrogen sulfate
原文传递
导出
摘要 目的根据硫酸氢氯吡格雷的波谱特征揭示其手性特征和多晶型差异。方法采用红外光谱、核磁共振、粉末X-衍射、比旋度和熔点测定等技术,检测了硫酸氢氯吡格雷的波谱特征、晶面间距,旋光度和熔点等。结果硫酸氢氯吡格雷的手性构型在NOESY谱中得到表达,且S型(+55.05°)的比旋度不同于R型(-55.40°);Ⅰ型晶和Ⅱ型晶在红外光谱波数568、590 cm-1表现出明显的差异,在粉末X-衍射的晶面间距出现多处差异,且Ⅰ型晶的熔点比Ⅱ型晶高8℃。结论具有典型手性结构和多晶结构的硫酸氢氯吡格雷通过多维核磁共振谱和比旋度测定表现出手性结构特征;通过红外光谱、粉末X-衍射和熔点可区分出晶型特征。 OBJECTIVE To reveal the chirality and polymorphs of Clopidogrel hydrogen sulfate according to its spectrum feature.METHODS On the basis of IR,NMR,XRD,specific optical rotation and melting point analyses,the sample’s spectrum,interplanar spacing,optical rotation and melting point were detected.RESULTS The stereo configuration of the sample was reflected in NOESY.Specific optical rotation of the sample,configuration S,was + 55.05°,differed from-55.4° of configuration R.Besides,the sample formⅠand formⅡ showed apparent difference in IR at the wave number of 568 cm-1 and 590 cm-1,and in several XRD interplanar spacing.Melting point of formⅠ was 8 ℃ higher than that of formⅡ.CONCLUSION Clopidogrel hydrogen sulfate is a typical example of both polymorphs and chiral structure.Chirality of Clopidogrel hydrogen sulfate can be explained through NOESY and specific optical rotation,and crystal form can be distinguished by IR,XRD and melting point.
出处 《华西药学杂志》 CAS CSCD 北大核心 2012年第4期359-361,共3页 West China Journal of Pharmaceutical Sciences
关键词 硫酸氢氯吡格雷 手性 多晶型 Clopidogrel hydrogen sulfate Chirality Polymorphs
  • 相关文献

参考文献6

二级参考文献52

  • 1张国宏,段亚波,李翼,吴松.盐酸阿替卡因的多晶型研究[J].中国新药杂志,2004,13(9):813-816. 被引量:4
  • 2程卯生,王敏伟,缪锦来,薛淑英,孙建春,沈建民.法莫替丁的多晶型与生物利用度[J].中国药物化学杂志,1994,4(2):110-117. 被引量:16
  • 3李更,王丽韫,郑建全,刘河,仲伯华,刘克良.盐酸苯环壬酯左旋体及光学异构体抗动物晕动病药效学研究[J].中华航空航天医学杂志,2006,17(2):87-91. 被引量:6
  • 4MIZUTA Y, IMAIZUMI T. Alpha beta-blockers for patients with hypertension [ J ]. Nippon Rinsho ,2006,64 ( S6 ) : 305 - 309. 被引量:1
  • 5BARDSLEY H,GRISTWOOD R,BAKER H,et al. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers [ J ]. Br J Clin Pharmacol, 1998,46 ( 3 ) :245 - 249. 被引量:1
  • 6PATIL PA, KOTHEKAR MA. Development of safer molecules through chirality[ J]. Indian J Med Sci,2006,60(10) :427 -437. 被引量:1
  • 7FDA. FDA'S POLICY STATEMENT FOR THE DEVELOPMENT OF NEW STEREOISOMERIC DRUGS. 1992[EB/OL].[2005 - 07 - 06 ]. http ://www. fda. gov/cder/guidance/stereo.html. 被引量:1
  • 8Health Canada. Stereochemical issues in chiral drug development [ EB/OL]. [ 2000 -02 - 14 ]. http://www, hc-sc.gc. ca/dhpmps/prodpharma/applic-demande/guide-ld/chem/stereo_e.html. 被引量:1
  • 9国家食品药品监督管理局.药品注册管理办法[EB/OL].[2007-07-10].http://www.sda.gov.cn/WS01/CL0053/24529.html. 被引量:8
  • 10Schror K.The basic pharmacology of ticlopidine and clopidogrel[J].Platelets,1993,4(5):252-261. 被引量:1

共引文献39

同被引文献64

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部